• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MGZ
Click for more information
0.00% 2.0¢

MEDIGARD LIMITED

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
MGZ
Is this the end ofMGZ 		17/03/19 6 1.5K
17/03/19 Last post  Ozzybear Comments Created with Sketch.  6  Views Created with Sketch.  1.5K 
MGZ
Ann: Suspension of Trading update 		15/03/19 0 249
15/03/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  249 
MGZ
Ann: Suspension from Official Quotation 		08/03/19 0 213
08/03/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  213 
MGZ
Ann: Half Yearly Report and Accounts 		27/02/19 0 121
27/02/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  121 
MGZ
Ann: License Agreement with Kunovus Pty Ltd 		27/02/19 30 4.2K
27/02/19 Last post  Sector Comments Created with Sketch.  30  Views Created with Sketch.  4.2K 
MGZ
Ann: Appendix 4C - quarterly 		31/01/19 0 105
31/01/19 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  105 
MGZ
News: MGZ Medigard Says Company Envisages Raising Capital In Near Term 		11/12/18 0 170
11/12/18 Last post  Hot News Comments Created with Sketch.  0  Views Created with Sketch.  170 
MGZ
Ann: Medigard KT009 project and funding strategy 		11/12/18 0 190
11/12/18 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  190 

See All Discussions arrow Created with Sketch.

Top Stories

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

Vitrafy Life Sciences Limited (ASX:VFY) has defied this month’s odds to become the only newly-listed Australian company to survive a surprisingly rough November (for newcomers, at least) without sagging below its IPO price.The cryopreservation biotech did give some back on Friday,...
Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia New Zealand’s Reserve Bank has taken a bold step, slashing rates by 50 basis points to 4.25% @ its third cut in just four months. Meanwhile, the Reserve Bank of Australia holds firm at 4.35%, its highest rate in over a decade.This stark policy divergence highlights contrasting glo...
Parkes Au-Cu project to 'transform' Adavale Resources with key targets Adavale Resources Ltd has entered into an all-scrip acquisition of the Parkes gold and copper project in New South Wales
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.